Epidermal growth factor receptor (EGFR) inhibition on non-small-cell lung cancer treatment

Abstract

Non small cell lung cancer (NSCLC) remains a significant clinical and social problem. In the last period there has been a steady increase a incidence in women and men. Results of surgical treatment, radiotherapy and chemotherapy have reached a plateau. Perspectives for pharmacological treatment of NSCLC determines understanding the molecular mechanisms responsible for tumor growth and resistance. The introduction of molecularly targeted drugs is an important step in the treatment of NSCLC. Targeted treatment includes the use of monoclonal antibodys, anti-angiogenic treatment and small molecule tyrosine kinase inhibitors. Identity of predictive factors plays a huge role for targeting treatment optimization.
Onkol. Prak. Klin. 2011; 7, 4: 177–182